Tulane Home Tulane Shield logo linking to site home page

Bladder Clinical Trials

A Phase 3 Randomized, Double-Blind, Multi-Center Study of Adjuvant Nivolumab versus Placebo in Subjects with High-Risk Invasive Urothelial Carcinoma (CA209-274).
More Information

A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer (NILE)
More Information

A Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Chemotherapy for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer (EV-103)
More Information

A Phase II Study of Ipilimumab, CabOzantinib, and NIvolumab in Rare Genitourinary Cancers (ICONIC)
More Information

A Trial of Perioperative Pembrolizumab Alone or Together with Enfortumab Vedotin for Cisplatin-Ineligible Participants with Muscle-Invasive Bladder Cancer (MIBC)
More Information

AmbisPective ObservATional Multi-centeR Study for FIrst Line Maintenance of Avelumab in UroThelIal CarcInoma (MS100070_0113)